Feature | June 10, 2014

Real-Time Radiation Monitoring Reduces Patient, Cardiologist Exposure

RadiCure study evaluates device that beeps upon radiation exposure

June 10, 2014 — A real-time monitoring device that beeps in the presence of high doses of radiation can help reduce patient and interventional cardiologist exposure to radiation during cardiac catheterization, according to results of the RadiCure study presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.

Radiation exposure during cardiac catheterization can place both the patient and the physician at risk. Advances in imaging equipment have helped reduce patient exposure, but physician exposure is typically only measured months later. In the study presented at SCAI, researchers monitored physician and patient radiation exposure using a real-time, personal radiation monitoring device called the Bleeper Sv. The device sounds every 15 minutes in response to normal background radiation and increases its beep rate as radiation exposure increases.

For the study, 505 patients undergoing left cardiac catheterization procedures were randomized to use or not use the monitoring device. Procedure times and patient characteristics were comparable in both study groups. Following the procedure, patient and interventional cardiologist radiation exposure was measured.

Researchers found that compared to the control group, use of the monitoring device led to a significant decrease in operator exposure [0.9 (0.4-1.7) vs 1.4 (0.6-2.5) mrem, p<0.001 for the first operator and 0.5 (0.2-1.0) vs 0.7 (0.4-1.4) mrem, p<0.001 for the second operator]. Patient radiation exposure did not differ significantly between the two groups; however, there was a trend for lower Air Kerma and Dose Area Product radiation in the Bleeper Sv group [0.855 (0.58-1.507) vs 0.989 (0.610-1.802) Gray, p=0.153 and 76.68 (52.98-133.53) vs 84.61 (55.37-161.20) Gray*cm2, p=0.125, respectively].

“Use of a personal radiation monitoring device that provides auditory feedback helps reduce both the patient and the interventional cardiologist’s exposure,” said Georgios Christopoulos, M.D., research fellow at VA North Texas Health Care System and the University of Texas Southwestern Medical Center.

“The device allows for immediate reaction that can limit exposure, unlike current monitoring that physicians undergo months after exposure,” said Emmanouil Brilakis, M.D., Ph.D., FSCAI, director of the cardiac catheterization laboratories at VA North Texas Health Care System, associate professor of medicine at the University of Texas Southwestern Medical Center and the study’s principal investigator.

For more information: www.scai.org

Related Content

News | Cath Lab| May 24, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions took place May 4-7, 2016
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study
News | Intravascular Imaging| May 20, 2016
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
clot, coronary thrombus, antiplatelet therapt, DAPT

An intravascular ultrasound (IVUS) image of a thrombus formed in a coronary artery.  While there are guidelines for antiplatelet therapy, there are still questions over the duration of such therapy. 

Feature | Antiplatelet and Anticoagulation Therapies| May 19, 2016 | Marianne Pop, Pharm.D., BCPS
There are many opinions on the duration of dual antiplatelet therapy (DAPT), highlighted at the 2016 American College
bioabsorbable vascular graft, children, feasibility study, Bakoulev Center Moscow, AATS 2016 meeting

Image courtesy of Bakoulev Scientific Center for Cardiovascular Surgery

News | Stent Grafts| May 18, 2016
Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the...
Technology | Cardiac Imaging| May 18, 2016
May 18, 2016 — The Intersocietal Accreditation Commission (IAC) recently announced its launch of the IAC QI Self-Asse
NeoChord, DS1000 System, FDA approval, U.S. pivotal trial
News | Heart Valve Technology| May 17, 2016
NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
Biotronik, Magmaris bioresorbable magnesium scaffold, BIOSOLVE-II Trial, 12-month results, EuroPCR 2016
News | Stents Bioresorbable| May 17, 2016
Biotronik presented 12-month data from the BIOSOLVE-II trial during a Hotline Session at EuroPCR 2016.
Overlay Init